ArticleJournal of biomedical research2026
Role of stem cells in ocular diseases: Progress and challenges.
Article in Journal of biomedical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular diseases, including corneal disease, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and retinopathy of prematurity, can significantly impair vision and reduce quality of life. Because degenerated cells in these diseases are unable to regenerate, treatments for these conditions have limited efficacy. Stem cell therapies are revolutionizing the treatment of degenerative eye conditions, enabling structural and functional restoration through mechanisms such as cell replacement and paracrine signaling. This review examines advances in stem cell therapy for ocular diseases, from preclinical studies to early clinical trials, focusing on various types of stem cells, including embryonic stem cells, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells. Significant progress has been made with iPSC-derived retinal pigment epithelial cell transplantation in AMD treatment, showing cell survival in trials, and with mesenchymal stem cells for corneal repair through anti-inflammatory effects. Challenges remain, such as controlling differentiation to prevent tumorigenesis, managing immune rejection, and ensuring manufacturing processes that comply with Good Manufacturing Practice standards. By integrating mechanistic insights with translational strategies, this review outlines pathways to optimize stem cell therapies for previously intractable ocular diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.